BioNTech SE announced the expansion of its strategic collaboration with Regeneron to advance the company’s FixVac candidate BNT116 in combination with Libtayo®, a PD-1 inhibitor, in advanced non-small cell lung cancer.
[BioNTech SE]
Sorry, but the selected Zotpress account can't be found.